- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 3, 2024Can You Keep a Secret? Privacy Laws and Civil Litigation
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Spring 2020
This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same information for proceedings before the Patent Trial and Appeal Board concerning Orange Book-listed patents.
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Celgene Corp. v. Mylan Pharms. Inc., 20-0003 (N.D.W.V.) | Jan. 3, 2020 | Hon. Irene M. Keeley | Revlimid® (lenalidomide capsules) | 7,189,740 7,465,800 7,855,217 7,968,569 8,404,717 8,530,498 8,648,095 9,056,120 9,101,621 9,101,622 |
| Exela Pharma Sciences, LLC v. Avadel Legacy Pharms., LLC, 20-0024 (D. Del.) | Jan. 7, 2020 | Hon. Maryellen Noreika | Elcys® (cysteine HCl for injection) Nouress™ (cysteine HCl for injection) | 10,478,453 |
| Celgene Corp. v. Aurobindo Pharma Ltd., 20-0315 (D.N.J.) | Jan. 8, 2020 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,465,800 7,855,217 7,968,569 8,530,498 8,648,095 9,101,621 9,101,622 |
| Almirall, LLC v. Zydus Pharms. (USA) Inc., 20-0343 (D.N.J.) | Jan. 9, 2020 | Hon. Freda L. Wolfson | Aczone® (dapsone gel) | 9,517,219 |
| Almirall, LLC v. Mylan Pharms. Inc., 20-0006 (N.D.W.V.) | Jan. 9, 2020 | Hon. Irene M. Keeley | Aczone® (dapsone gel) | 9,517,219 |
| Amgen Inc. v. Torrent Pharma Inc., 20-0065 (D. Del.) | Jan. 16, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Merck Sharp & Dohme Corp. v. Actavis Labs. FL, Inc., 20-0534 (D.N.J.) | Jan. 16, 2020 | Hon. Claire C. Cecchi | Dificid® (fidaxomicin tablets) | 7,906,489 8,586,551 7,378,508 7,863,249 8,859,510 |
| Novartis Pharms. Corp. v. Alembic Pharms. Ltd., 20-0074 (D. Del.) | Jan. 17, 2020 | Hon. Leonard P. Stark | Entresto® (sacubitril / valsartan tablets) | 8,101,659 8,796,331 8,877,938 9,388,134 |
| Amgen Inc. v. Zydus Pharms. (USA) Inc., 20-0075 (D. Del.) | Jan. 17, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Merck Sharp & Dohme Corp. v. Actavis Labs. FL, Inc., 20-20217 (S.D. Fla.) | Jan. 17, 2020 | Hon. Ursula Ungaro | Dificid® (fidaxomicin tablets) | 7,906,489 8,586,551 7,378,508 7,863,249 8,859,510 |
| Vanda Pharms. Inc. v. Apotex Inc., 20-0083 (D. Del.) | Jan. 21, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,449,176 |
| Amgen Inc. v. Zydus Pharms. (USA) Inc., 20-0678 (D.N.J.) | Jan. 21, 2020 | Hon. Freda L. Wolfson | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Vanda Pharms. Inc. v. Teva Pharms. USA, Inc., 20-0093 (D. Del.) | Jan. 22, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,449,176 |
| Amgen Inc. v. Bionpharma, Inc., 20-0105 (D. Del.) | Jan. 23, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Relypsa, Inc. v. Alkem Labs. Ltd., 20-0106 (D. Del.) | Jan. 23, 2020 | Hon. Maryellen Noreika | Veltassa® (patiromer sorbitex calcium powder for oral suspension) | 8,337,824 9,492,476 9,925,212 |
| Merck Sharp & Dohme Corp. v. Sandoz Inc., 20-0783 (D.N.J.) | Jan. 23, 2020 | Hon. Brian R. Martinotti | Noxafil® (posaconazole oral suspension) | 8,263,600 |
| Janssen Products, L.P. v. Zydus Pharms. (USA) Inc., 20-0787 (D.N.J.) | Jan. 23, 2020 | Hon. Freda L. Wolfson | Prezista® (darunavir tablets) | 7,700,645 8,518,987 7,126,015 7,595,408 |
| Amgen Inc. v. Annora Pharma Private Ltd., 20-0122 (D. Del.) | Jan. 24, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Amgen Inc. v. Centaur Pharms. Private Ltd., 20-0123 (D. Del.) | Jan. 24, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Novartis Pharms. Corp. v. Apotex Inc., 20-0133 (D. Del.) | Jan. 28, 2020 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 10,543,179 |
| Sucampo Gmbh v. Zydus Pharms. (USA) Inc., 20-0936 (D.N.J.) | Jan. 28, 2020 | Hon. Freda L. Wolfson | Amitiza® (lubiprostone capsules) | 7,795,312 8,026,393 8,338,639 8,779,187 8,748,481 |
| Amgen Inc. v. MSN Pharms., Inc., 20-0137 (D. Del.) | Jan. 29, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Pfizer Inc. v. Viwit Pharm. Co., Ltd., 20-0160 (D. Del.) | Jan. 31, 2020 | Hon. Colm F. Connolly | Chantix® (varenicline tartrate tablets) | 6,410,550 6,890,927 7,265,119 |
| Silvergate Pharms., Inc. v. CMP Development LLC, 20-0161 (D. Del.) | Jan. 31, 2020 | Hon. Leonard P. Stark | Qbrelis® (Lisinopril oral solution) | 9,463,183 9,616,096 9,814,751 10,039,800 10,265,370 10,406,199 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00368 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 8,163,723 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00369 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 8,168,620 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00370 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 9,259,428 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00371 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 9,901,585 |
| Boehringer Ingelheim Pharms. Inc. v. Mylan Pharms. Inc., 20-0019 (N.D.W.V.) | Feb. 5, 2020 | Hon. Irene M. Keeley | Tradjenta® (linagliptin tablets) | 9,486,526 |
| Boehringer Ingelheim Pharms. Inc. v. Aurobindo Pharma Ltd., 20-0023 (N.D.W.V.) | Feb. 5, 2020 | Hon. John Preston Bailey | Tradjenta® (linagliptin tablets) | 9,486,526 |
| Gilead Sciences, Inc. v. Apotex, Inc., 20-0189 (D. Del.) | Feb. 7, 2020 | Hon. Maryellen Noreika | Vemlidy® (tenofovir alafenamide tablets) Descovy® (emtricitabine / tenofovir alafenamide tablets) Odefsey® (emtricitabine / rilpivirine / tenofovir alafenamide tablets) | 7,390,791 7,803,788 8,754,065 9,296,769 |
| American Regent, Inc. v. Pharmacosmos Therapeutics Inc., 20-1350 (D.N.J.) | Feb. 7, 2020 | Hon. Brian R. Martinotti | Monoferric® (ferric derisomaltose for injection) | 8,431,549 10,478,450 |
| Allergan Sales, LLC v. Breckenridge Pharm., Inc., 20-0199 (D. Del.) | Feb. 10, 2020 | Hon. Mitchell S. Goldberg | Saphris® (asenapine maleate sublingual tablets) | 5,763,476 |
| AstraZeneca AB v. Alembic Pharms. Ltd., 20-0202 (D. Del.) | Feb. 11, 2020 | Hon. Richard G. Andrews | Tagrisso® (osimertinib mesylate tablets) | 10,183,020 |
| Vifor (Int’l) AG v. Mylan Labs. Ltd., 20-1647 (D.N.J.) | Feb. 14, 2020 | Hon. Freda L. Wolfson | Injectafer® (ferric carboxymaltose for injection) | 10,519,252 |
| Vifor (Int’l) AG v. Sandoz Inc., 20-1649 (D.N.J.) | Feb. 14, 2020 | Hon. Freda L. Wolfson | Injectafer® (ferric carboxymaltose for injection) | 10,519,252 |
| Vanda Pharms. Inc. v. MSN Pharms. Inc., 20-0235 (D. Del.) | Feb. 19, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,376,487 |
| Astellas US LLC v. Int’l Medication Systems, Ltd., 20-0273 (D. Del.) | Feb. 25, 2020 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) | 8,106,183 RE47,301 8,524,883 |
| Boehringer Ingelheim Pharms. Inc. v. Annora Pharma Private Ltd., 20-0277 (D. Del.) | Feb. 25, 2020 | Hon. Colm F. Connolly | Glyxambi® (empagliflozin / linagliptin tablets) | 10,258,637 |
| Millennium Pharms., Inc. v. Sun Pharm. Indus. Ltd., 20-0289 (D. Del.) | Feb. 27, 2020 | Hon. Colm F. Connolly | Ninlaro® (ixazomib citrate capsules) | 7,442,830 8,859,504 9,175,017 |
| ViiV Healthcare Co. v. Lupin Ltd., 20-0293 (D. Del.) | Feb. 28, 2020 | Hon. Mitchell S. Goldberg | Juluca® (dolutegravir sodium / rilpivirine HCl tablets) | 9,242,986 10,426,780 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-0300 (D. Del.) | Feb. 28, 2020 | Hon. Leonard P. Stark | Xeljanz® (tofacitinib citrate tablets) | 6,965,027 7,301,023 RE41,783 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-0301 (D. Del.) | Feb. 28, 2020 | Hon. Leonard P. Stark | Xeljanz XR® (tofacitinib extended-release tablets) | 6,965,027 7,301,023 RE41,783 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-2222 (D.N.J.) | Feb. 28, 2020 | Hon. Freda L. Wolfson | Xeljanz XR® (tofacitinib extended-release tablets) | 6,965,027 7,301,023 RE41,783 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-2227 (D.N.J.) | Feb. 28, 2020 | Hon. Freda L. Wolfson | Xeljanz® (tofacitinib citrate tablets) | 6,965,027 7,301,023 RE41,783 |
| Vanda Pharms. Inc. v. MSN Pharms. Inc., 20-0318 (D. Del.) | Mar. 3, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,449,176 |
| Takeda Pharms. U.S.A., Inc. v. Alkem Labs. Ltd., 20-0325 (D. Del.) | Mar. 3, 2020 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets)) | 7,906,519 7,935,731 8,093,298 7,964,648 8,093,297 7,619,004 7,601,758 7,820,681 7,915,269 7,964,647 7,981,938 8,093,296 8,097,655 8,415,395 8,415,396 8,440,721 8,440,722 |
| Encore Dermatology Inc. v. Glenmark Pharms. Ltd., 20-2509 (D.N.J.) | Mar. 6, 2020 | Hon. Kevin McNulty | Impoyz® (clobetasol propionate cream) | 9,956,231 |
| Astellas US LLC v. Gland Pharma Ltd., 20-0347 (D. Del.) | Mar. 9, 2020 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) | 8,106,183 RE47,301 8,524,883 |
| Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc., 20-2576 (D.N.J.) | Mar. 10, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Celgene Corp. v. Apotex Inc., 20-2593 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Breckenridge Pharm., Inc., 20-2597 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Hetero Labs Ltd., 20-2601 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Aurobindo Pharma Ltd., 20-2606 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Dr. Reddy’s Labs., Ltd., 20-2607 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Mylan Pharms. Inc., 20-2608 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Teva Pharms. USA, Inc., 20-2614 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Bausch Health US, LLC v. Aleor Dermaceuticals Ltd., 20-2735 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Alkem Labs. Ltd., 20-2737 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Aurobindo Pharma USA Inc., 20-2738 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Amneal Pharms. LLC v. Cubist Pharms. LLC, IPR2020-00193 (PTAB) | Nov. 27, 2019 | N/A | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Bausch Health US, LLC v. KVK-Tech, Inc., 20-2742 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Lupin Ltd., 20-2744 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Strides Pharma Inc., 20-2746 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Taro Pharms. U.S.A., Inc., 20-2747 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Zydus Pharms. (USA) Inc., 20-2748 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Mylan Pharms. Inc., 20-2749 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Merck Sharp & Dohme B.V. v. Gland Pharma Ltd., 20-2750 (D.N.J.) | Mar. 12, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Teva Pharms. USA, Inc., 20-2751 (D.N.J.) | Mar. 12, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Braintree Labs., Inc. v. Alkem Labs. Ltd., 20-0362 (D. Del.) | Mar. 13, 2020 | Hon. Colm F. Connolly | Suprep® Bowel Prep Kit (sodium sulfate / potassium sulfate / magnesium sulfate oral lavage solution) | 6,946,149 |
| Merck Sharp & Dohme B.V. v. Lupin Ltd., 20-2786 (D.N.J.) | Mar. 13, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Mankind Pharma Ltd., 20-2787 (D.N.J.) | Mar. 13, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 6,949,527 |
| Bausch Health US, LLC v. Mylan Pharms. Inc., 20-0046 (N.D.W.V.) | Mar. 13, 2020 | Hon. Irene M. Keeley | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Exela Pharma Sciences, LLC v. Eton Pharms., Inc., 20-0365 (D. Del.) | Mar. 16, 2020 | Hon. Maryellen Noreika | Elcys® (cysteine HCl for injection) | 10,478,453 10,583,155 |
| Merck Sharp & Dohme B.V. v. Fresenius Kabi USA, LLC, 20-2892 (D.N.J.) | Mar. 16, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Braintree Labs., Inc. v. Alkem Labs. Ltd., 20-2904 (D.N.J.) | Mar. 16, 2020 | Hon. Peter G. Sheridan | Suprep® Bowel Prep Kit (sodium sulfate / potassium sulfate / magnesium sulfate oral lavage solution) | 6,946,149 |
| Merck Sharp & Dohme B.V. v. Dr. Reddy’s Labs., Inc., 20-2909 (D.N.J.) | Mar. 16, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Fisiopharma S.R.L., 20-2964 (D.N.J.) | Mar. 17, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Sun Pharm. Indus., Inc., 20-3007 (D.N.J.) | Mar. 18, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Hoffmann-La Roche, Inc. v. Fresenius Kabi USA, LLC, 20-0394 (D. Del.) | 19-Mar-20 | Hon. Richard G. Andrews | Alcensa® (alectinib HCl capsules) | 9,126,931 9,440,922 9,365,514 10,350,214 |
| Merck Sharp & Dohme B.V. v. Zydus Pharms. (USA) Inc., 20-3068 (D.N.J.) | Mar. 19, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. USV Private Ltd., 20-3072 (D.N.J.) | Mar. 19, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Pharmacyclics LLC v. Sun Pharma Global FZE, 20-0403 (D. Del.) | Mar. 20, 2020 | Hon. Colm F. Connolly | Imbruvica® (ibrutinib tablets) | 10,478,439 |
| Mitsubishi Tanabe Pharma Corp. v. Aurobindo Pharma USA, Inc. 20-3102 (D.N.J.) | Mar. 20, 2020 | Hon. Renee Marie Bumb | Invokamet XR® (canagliflozin / metformain HCl extended-release tablets) | 7,943,582 8,513,202 |
| Mitsubishi Tanabe Pharma Corp. v. Aurobindo Pharma USA, Inc. 20-3106 (D.N.J.) | Mar. 20, 2020 | Hon. Freda L. Wolfson | Invokamet XR® (canagliflozin / metformain HCl extended-release tablets) | 7,943,788 8,222,219 8,785,403 |
| Merck Sharp & Dohme B.V. v. Aspiro Pharma Ltd., 20-3112 (D.N.J.) | Mar. 20, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 6,949,527 |
| Merck Sharp & Dohme B.V. v. Sandoz Inc., 20-3117 (D.N.J.) | Mar. 20, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Cubist Pharms. LLC v. Mylan Pharms Inc., 20-3168 (D.N.J.) | Mar. 23, 2020 | Hon. Brian R. Martinotti | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Novartis Pharms. Corp. v. Lupin Atlantis Holdings, S.A., 20-0415 (D. Del.) | Mar. 24, 2020 | Hon. Leonard P. Stark | Entresto® (sacubitril / valsartan tablets) | 8,101,659 8,796,331 8,877,938 9,388,134 |
| Cubist Pharms. LLC v. Mylan Pharms. Inc., 20-0052 (N.D.W.V.) | Mar. 24, 2020 | Hon. Irene M. Keeley | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc., 20-3229 (D.N.J.) | Mar. 25, 2020 | Hon. Michael A. Shipp | Sprycel® (dasatinib tablets) | 7,491,725 |
| Merck Sharp & Dohme B.V. v. Mylan API US LLC, 20-3270 (D.N.J.) | Mar. 25, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Salix Pharms., Ltd. v. Norwich Pharms., Inc., 20-0430 (D. Del.) | Mar. 26, 2020 | Hon. Richard G. Andrews | Xifaxan® (rifaximin tablets) | 7,045,620 7,612,199 7,902,206 7,906,542 7,915,275 8,158,644 8,158,781 8,193,196 8,309,569 8,518,949 8,642,573 8,741,904 8,829,017 8,835,452 8,853,231 8,946,252 8,969,398 9,271,968 9,421,195 9,629,828 10,314,828 10,335,397 10,456,384 |
| Ferring Pharms. Inc. v. Fresenius Kabi USA, LLC, 20-0431 (D. Del.) | Mar. 26, 2020 | Hon. Maryellen Noreika | Firmagon® (degarelix for injection) | 9,579,359 9,415,085 8,841,081 9,877,999 8,828,938 |
| Merck Sharp & Dohme B.V. v. MSN Labs. Private Ltd., 20-3314 (D.N.J.) | Mar. 26, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Mallinckrodt Hospital Products IP Ltd. v. Baxter Healthcare Corp., 20-0434 (D. Del.) | Mar. 27, 2020 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) | 9,399,012 9,610,265 9,987,238 10,383,834 6,992,218 |
GENERICally Speaking Spring 2020
Related Professionals
Christopher A. Pinahs
Partner
Haroon N. Mian
Associate
GENERICally Speaking Spring 2020
VOL. 9, NO. 4 Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.